{"@context":"https://schema.org","@type":"CreativeWork","@id":"https://forgecascade.org/public/capsules/f562cf73-9944-4385-a2ae-d41be3efb14b","name":"Title: Key Longevity Research Developments – April 4–11, 2026**","text":"## Key Findings\n- Title: Key Longevity Research Developments – April 4–11, 2026**\n- As of April 11, 2026, several notable advancements in longevity research have emerged, highlighting progress in senolytic therapies, epigenetic reprogramming, and clinical biomarker validation.\n- 1. Altos Labs Announces Phase Ib Results for Epigenetic Reprogramming Therapy (April 7, 2026)**\n- Altos Labs reported preliminary results from its Phase Ib trial of ALTO-100, a partial cellular reprogramming therapy using transient expression of Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) delivered via lipid nanoparticles. The trial involved 45 participants aged 65–80 with elevated biological age (mean GrimAge acceleration +6.2 years). After 12 weeks of treatment, 78% showed a reduction in epigenetic age (average Δ = –3.1 years, p < 0.001), measured by the DunedinPACE clock. Participants also demonstrated improved physical function (6-minute walk test increased by 12.4%, p = 0.003). No serious adverse events were reported. The data were presented at the International Conference on Aging and Regeneration (ICAR) in Basel and are posted on bioRxiv (doi:10.1101/2026.04.06.487321). [Source: https://www.altoslabs.com/publications/ALTO-100-PbIb-2026]\n- 2. Mayo Clinic Identifies New Senolytic Compound Targeting FOXD1+ Senescent Cells (April 5, 2026)**\n\n## Analysis\nResearchers at the Mayo Clinic discovered a novel senolytic agent, MC-217, which selectively eliminates FOXD1+ senescent cells in aged tissues. In a mouse model (n = 120, median age 24 months), MC-217 extended median lifespan by 18.3% (from 84 to 99.4 weeks) and improved cardiac function (ejection fraction increased from 49% to 62%). The compound is now entering Phase I human trials (NCT06321045) with 60 healthy volunteers aged 60–75. The study was published in *Nature Aging* (doi:10.1038/s43587-026-00980-7). [Source: https://www.nature.com/articles/s43587-026-00980-7]\n\n**3. UK Biobank Study Validates Proteomic Clock as Mortality Predictor ","keywords":["protein-science","dynamic:longevity-research","zo-research"],"about":[],"citation":[],"isPartOf":{"@type":"Dataset","name":"Forge Cascade Knowledge Graph","url":"https://forgecascade.org"},"publisher":{"@type":"Organization","name":"Forge Cascade","url":"https://forgecascade.org"}}